Business Context and Reporting Period
This Form 8-K filing by iBio, Inc. is dated January 25, 2012. The report addresses Item 3.01 regarding the notice of delisting or failure to satisfy a continued listing rule. The company previously received notice from NYSE Amex LLC on November 4, 2011, citing non-compliance with Section 1003(a)(iv) due to substantial losses and impaired financial condition.
Key Financial Metrics
- Capital Raised: Gross proceeds of approximately $10 million from a public offering of common stock and warrants.
- Offering Date: Priced on January 10, 2012, and closed on January 13, 2012.
- Adjusted Equity and Cash: Based on preliminary balance sheet data as of December 31, 2011, adjusted stockholders' equity and cash exceed $9 million following the offering.
- Liquidity: Management states the company has sufficient working capital to fund operations for the next 12 months.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures for the current period.
Material Changes
The primary material change is the successful completion of an equity offering that exceeded the initial compliance plan target. The original plan required gross proceeds of approximately $5 million by January 25, 2012. The company instead raised approximately $10 million, significantly improving its financial position relative to the Exchange's concerns about its ability to continue operations.
Outlook, Risks, and Management Commentary
Management believes the company has completed its compliance plan and is now in full compliance with all applicable requirements for continued listing. The company is currently awaiting formal confirmation from the Exchange Staff. Upon receipt of this confirmation, iBio intends to make a public announcement. The primary risk remains the potential for delisting if the Exchange does not validate the compliance status, though management expresses confidence based on the improved capital position.
Investor Verification Checklist
- Confirm receipt of official compliance confirmation from NYSE Amex LLC Staff.
- Verify the final audited balance sheet reflecting the $10 million in proceeds.
- Monitor for any public announcement regarding the listing status following the expected confirmation.
- Review the terms of the common stock purchase warrants issued in the offering.